Pfizer’s Q1 2024 Results Highlight Robust Portfolio Growth and Profitability
Pfizer Inc. (NYSE: PFE) saw its share price surge over 5% following the release of...
US Legislature Reviews BioSecurity Bill to Sever Biotech Industry Ties with Chinese Companies
On May 15, 2024, the US House Oversight Committee is set to review a “BioSecurity”...
Kelun-Biotech’s RET Inhibitor A400 Advances to Phase II Trial with FDA Approval
Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422), a Chinese pharmaceutical company, has announced that its...
Everest Medicines’ Nefecon Secures Market Approval for IgAN Treatment in Hong Kong
Everest Medicines (HKG: 1952), a China-based pharmaceutical company, announced that it has received market approval...
Wondfo Biotech’s WELLlife Test Kit Receives FDA Nod for Home Use in the US
Guangzhou Wondfo Biotech Co., Ltd (SHE: 300482), a leading biotechnology company based in China, has...
United Imaging’s uMR Jupiter 5T Becomes First Ultra-High Frequency MRI System to Gain FDA Approval
Shanghai-based medical equipment manufacturer United Imaging Healthcare (UIH, SHA: 688271) has announced that it has...
HuidaGene’s MECP2 Duplication Syndrome Therapy Earns Positive EMA Opinion
HuidaGene (Shanghai) Biotechnology Co., Ltd, a biotech company based in China, has announced that it...
Hansoh Pharmaceutical Secures Exclusive Rights to QYuns Therapeutics’ QX004N in Greater China
Jiangsu QYuns Therapeutics Co., Ltd, a biopharmaceutical company based in China, has entered into a...
Well Lead Medical’s Stone Removal Sheath Gains Karl Storz as US Sole Agent
Well Lead Medical Co., Ltd (SHA: 603309), a Guangzhou-based specialist in medical catheters, has entered...
Shenzhen Hepalink Logs 5.55% Q1 Revenue Growth and 133% Net Profit Increase
Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399) has announced its financial results for the...
Zhejiang Hisun Pharmaceutical’s Ex-President Li Yan Investigated for Graft
Zhejiang Hisun Pharmaceutical Co., Ltd (SHA: 600267), a Chinese pharmaceutical company, has announced that Li...
Jacobio Pharma’s Glecirasib Shows Promise in Phase II Study for NSCLC Presented at ASCO
Jacobio Pharma (HKG: 1167), a biopharmaceutical company based in China, has announced the presentation of...
BeiGene’s Anti-PD-1 Therapy Tislelizumab Expands Indication for Gastric Cancer in China
BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced that its anti-PD-1 therapy, tislelizumab, has...
China’s National Procurement Office Announces Continuous VBP for Joint Prosthetics
The National High-Value Medical Consumables Joint Procurement Office in China has initiated a new round...
China’s NMPA Approves Shenzhen Chipscreen’s Chidamide for DLBCL Indication
Shenzhen Chipscreen Biosciences Co., Ltd, a biopharmaceutical company based in China, announced that it has...
Siemens Healthineers AG Partners with Haidian District Government to Boost Medical Innovation in Beijing
Siemens Healthineers AG (ETR: SHL), a leading medical technology company based in Germany, has entered...
Hainan Poly Pharm’s Manufacturing Units Get GMP Nod From Saudi Food and Drug Authority
Hainan Poly Pharm Co., Ltd (SHE: 300630), a Chinese pharmaceutical company, announced that it has...
GBA Center of NMPA Launches Filing Guidance for Pharmaceutical Enterprises
The Guangdong-Hong Kong-Macau Greater Bay Area (GBA) Center for Drug Evaluation and Inspection, under the...
Keymed Biosciences’ IL-4Rα Monoclonal Antibody for Allergic Rhinitis Accepted by China NMPA
China-based biopharmaceutical company Keymed Biosciences Inc. (HKG: 2162) has announced that the National Medical Products...
Bristol-Myers Squibb’s Camzyos Approved by China’s NMPA for Hypertrophic Cardiomyopathy Treatment
Bristol-Myers Squibb (BMS; NYSE: BMY) has received marketing approval from China’s National Medical Products Administration...